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Aminoacyl-tRNA synthetases (aaRSs) ligate amino acids to
their cognate tRNAs, allowing them to decode the triplet code
during translation. Through different mechanisms aaRSs also
perform several non-canonical functions in transcription,
translation, apoptosis, angiogenesis and inﬂammation.
Drosophila has become a preferred system to model human
diseases caused by mutations in aaRS genes, to dissect effects
of reduced translation or non-canonical activities, and to study
aminoacylation and translational ﬁdelity. However, the lack of
a systematic annotation of this gene family has hampered
such studies. Here, we report the identiﬁcation of the entire set
of aaRS genes in the ﬂy genome and we predict their roles
based on experimental evidence and/or orthology. Further, we
propose a new, systematic and logical nomenclature for aaRSs.
We also review the research conducted on Drosophila aaRSs to
date. Together, our work provides the foundation for further
research in the ﬂy aaRS ﬁeld.
Introduction
Aminoacyl-tRNA synthetases (aaRSs) constitute an ancient
family of enzymes that catalyze aminoacylation reactions by
attaching amino acids to cognate tRNAs.1,2 The aminoacylation
reaction is a 2-step process (Fig. 1). In the first step, the amino
acid is activated by ATP to generate an aminoacyl-adenylate
intermediate. In the second step, the activated amino acid is
transferred to the 30 end of the tRNA bearing the appropriate
anticodon triplet that recognizes the corresponding codon in the
mRNA.3 Such an aminoacylated tRNA is referred to as aa-tRNA
and it can now be delivered to the ribosome for nascent
polypeptide synthesis. Because aaRSs recognize specific amino
acids and the corresponding tRNAs, they translate the nucleic
acid language into the amino acid language and thereby decode
the “second genetic code”.4 aaRSs are thus fundamental compo-
nents of the protein synthesis process in all cells of all species in
the 3 primary kingdoms of life.
There are 20 standard amino acids, and for each of them cells
are expected to express at least one aaRS. Two different criteria
may be used to categorize aaRSs. Based on their protein struc-
ture, class I aaRSs contain a characteristic Rossman fold catalytic
domain and usually function as monomeric or dimeric proteins,
while class II aaRSs contain 3 conserved motifs and are usually
dimeric or tetrameric.2,5 Alternatively, aaRSs may be classified
according to their subcellular sites of action: cytoplasmic, mito-
chondrial, or both cytoplasmic and mitochondrial (‘dual-
localized’).6,7
Interest in aaRSs has grown in recent years for 2 major rea-
sons. First, it has become apparent that aaRSs perform diverse
non-canonical functions in addition to their roles in protein syn-
thesis, including roles in regulation of transcription and transla-
tion, apoptosis, angiogenesis and inflammation.8,9 These
additional functions are mainly achieved by recruitment of other
protein complexes, acquisition of additional domains, or genera-
tion of novel protein fragments by alternative splicing or proteol-
ysis.8,10,11 Second, genetic studies have revealed that mutations
in many aaRS genes are associated with a wide variety of human
syndromes and diseases.7,12,13 For example, mutations in 5 genes
encoding cytoplasmic or dual-localized aaRSs have been identi-
fied in patients with (mainly dominantly inherited) peripheral
neuropathies, while 9 mitochondrial aaRS loci have been impli-
cated in heterogeneous recessive disorders.12 In most cases it is
not known how aaRS mutations cause the disease phenotypes-
whether through reduced translational activity, reduced aminoa-
cylation accuracy or through a defect in a non-canonical
function.
The powerful genetic tools available in Drosophila mela-
nogaster offer tremendous potential to explore genotype – pheno-
type relationships, while the high evolutionary conservation of
the tRNA aminoacylation reaction validates the modeling of
aaRS-associated diseases in this system.14,15 However, the full
complement of Drosophila aaRSs has not been accurately charac-
terized to date, and as a result the annotations in the FlyBase
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database have been incomplete and in some cases incorrect. For
example, prior to our recent study,16 the gene encoding mito-
chondrial PheRS was named as “Aats-phe, phenylalanyl-tRNA syn-
thetase” (implying a cytoplasmic role) while the genes encoding
the 2 subunits of the true cytoplasmic PheRS were unnamed.
The lack of a comprehensive and consistent set of aaRS annota-
tions in D. melanogaster potentially hampers understanding and
research of these fundamental enzymes in this key model
organism.
Here, we report our systematic analysis to identify and classify
all aaRSs in D. melanogaster. In so doing, we propose a new
nomenclature for Drosophila aaRS genes that is more explicit and
consistent with that used in the wider field. In addition, we
review the important aaRS studies that have been carried out in
flies to date to illustrate how this model organism has already
contributed to the field.
Identification of D. melanogaster aminoacyl-tRNA
synthetases
In a typical eukaryotic cell, there are cytoplasmic, mitochon-
drial, and dual-localized aaRSs.7 Because the number of standard
amino acids is 20, the total number of aaRSs is therefore expected
to be in the range of 20 to 40. We are aware of one previous
study that attempted to identify the D. melanogaster aaRSs17 –
this list of 20 different aaRSs, however, comprised a mixture of
cytoplasmic and mitochondrial factors.
We began our own study of D. melanogaster aaRSs by search-
ing FlyBase18 (FB2014_06) for genes with the prefix used in the
database for this set of genes, namely ‘Aats-’, for ‘Aminoacyl-
tRNA synthetase’. Only 22 aaRS genes were found by this
approach (Table S1), suggesting that additional aaRS genes
remained to be identified. Furthermore, reference to the location
of the enzyme was inconsistent or missing in several gene names:
7 of the 22 named genes encode mitochondrial aaRSs, but this
was indicated in only 2 cases; the names of the other 5 mitochon-
drial aaRS genes did not contain location information and would
therefore be wrongly considered to be cytoplasmic (or dual-
localized), particularly as the true cytoplasmic form was unnamed
in each case (see below).
In order to identify the full complement of fly genes encoding
aaRSs, we used the well-characterized set of human aaRS proteins
(obtained from the HGNC database19) to search for matching
D. melanogaster polypeptides in FlyBase (FB2014_06, Dmel
Annotation Release 6.03) using BLASTP. We also examined
ortholog predictions housed within FlyBase and the HGNC
databases, and searched for genes annotated with relevant Gene
Ontology terms and InterPro domains. The results are summa-
rized in Table 1. We found that 35 genes in the fly nuclear
genome encode 34 aaRS enzymes: 15 aaRSs are predicted to act
exclusively in the cytoplasm, 15 in the mitochondria, and 4 are
dual-localized. The reason for the gene count being one more
than the aaRS count is because the cytoplasmic phenylalanyl-
tRNA synthetase comprises 2 subunits encoded by 2 separate
genes.16 The reason for finding 19 (and not 20) aaRSs that act in
the cytoplasm is because the cytoplasmic glutamyl-prolyl-tRNA
synthetase (GluProRS) loads both Glu and Pro to their cognate
tRNAs.20 Finally the explanation for finding 19 (and not 20)
aaRSs that function in mitochondria is that there is no mitochon-
drial glutaminyl-tRNA synthetase (GlnRS; discussed below). It is
also worth noting that CG10802, CG8097 and Slimp
(CG31133), encode proteins containing domains associated with
alanyl-, arginyl- and seryl-tRNA synthetase activity, respectively
(Table S2). However, their overall similarities to the canonical
human and Drosophila proteins are relatively low, and it is known
that Slimp lacks aminoacylation activity.21 These three genes are
therefore not included in Table 1 and were not considered
further.
We propose a unified Drosophila nomenclature for aaRSs that
discriminates between the cytoplasmic and mitochondrial
enzymes, rather than one that describes their biochemical and
structural properties. This makes sense for work in a system that
has a strong emphasis on functional studies. Furthermore, this
nomenclature is widely used within the aaRS field. Thus we add
a ‘-m’ suffix to the symbols of genes encoding the mitochondrial
Figure 1. Aminoacyl-tRNA synthetase catalyzes a 2-step aminoacylation reaction. In the ﬁrst step, the aaRS activates the substrate amino acid. By con-
suming an ATP it forms an aa-AMP intermediate. In the second step, the aa-AMP is transferred to the acceptor end of the cognate tRNA, generating an
aa-tRNA that can be delivered to ribosomes for protein synthesis. aa, amino acid; aaRS, aminoacyl-tRNA synthetase; PPi, pyrophosphate.
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aaRSs. We also suggest that the ‘Aats-x’ format previously used
for aaRS genes in FlyBase is replaced with the more common
‘xRS‘ format, where x indicates the relevant amino acid. Finally,
we recommend using the 3-letter, rather than the single letter,
amino acid code because this is more explicit and more easily rec-
ognized as an amino acid when followed by ‘RS’ in the same
word and, again, it is a common convention in the field. With
this nomenclature, the gene symbol for the cytoplasmic tyrosyl-
tRNA synthetase is ‘TyrRS’, while ‘TyrRS-m’ is the designation
for the gene encoding the mitochondrial tyrosyl-tRNA synthe-
tase. While it might also make sense to add a distinguishing suffix
to the symbols of the dual-localized enzymes and genes, we have
opted to name them the same way as the cytoplasmic ones to
keep the symbols simple and short. The symbols and names of
all aaRSs following this proposed nomenclature are shown in full
in Table 1.
In the following parts, we will analyze the 3 groups of aaRSs
separately and will review the published work on them.
Cytoplasmic aminoacyl-tRNA synthetases
Cytoplasmic aaRSs charge tRNAs with cognate amino acids in
the cytoplasm. Some of these aaRSs are also able to translocate to
the nucleus and aminoacylation can also take place in this com-
partment.22 There are 16 genes encoding 15 cytoplasmic aaRSs
in D. melanogaster and these are able to charge 16 different amino
acids (Table 1). As mentioned, the discrepancies in these figures
are explained by the GluProRS gene encoding a protein with 2
enzymatic activities, and by the PheRS enzyme consisting of 2
different subunits encoded by 2 distinct genes. While cyto-
plasmic aaRS genes generally encode a single, unique polypep-
tide, it is noteworthy that GluProRS and ValRS, respectively,
encode each 2 different polypeptides, generated by alternative
promoter usage and alternative splicing, respectively (FlyBase).
The bifunctionality of GluProRS is unique among all aaRSs
and it has been well studied in various systems, including
flies.20,23 In bacteria and archaea, 2 distinct genes encode GluRS
and ProRS, and it seems that a gene fusion event occurred during
the evolution of metazoa.24 The GluProRS protein is composed
of 3 domains, the N-terminal domain with Glu-catalyzing activ-
ity, the C-terminal domain with Pro-catalyzing activity, and the
central domain with repeated motifs. In Drosophila, the Glu-
ProRS gene encodes 2 polypeptides, the full-length protein and
the C-terminal short protein. Their expression seems to be con-
trolled by different promoters and probably distinct transcrip-
tional regulators. The full-length protein is expressed throughout
development, while the C-terminal short protein is especially
abundant in 5–10 hours old embryos.23 Interestingly, the C-ter-
minal short protein is functional in Pro-tRNA aminoacylation
in vivo,23 thereby providing a second way to generate Pro-tRNA
in the cytoplasm.
An interesting feature of cytoplasmic aaRSs in higher eukar-
yotes (including flies) is that 8 aaRSs, together with 3 non-enzy-
matic factors, form a ‘multi-synthetase complex’ (MSC).9,20,25
The functional significance of the MSC is unclear, but the auxil-
iary factors are thought to be responsive to diverse signal trans-
duction pathways and thus provide a mechanism to coordinate
protein synthesis with other biological processes.9 In flies, the
auxiliary factors are encoded by the CG8235, CG12304, and
CG30185 genes, and we propose that these are named AIMP1,
AIMP2 and AIMP3 (aminoacyl-tRNA synthetase-interacting
multifunctional proteins 1, 2 and 3), respectively, to match the
nomenclature used in the wider field (Supplementary Table S2).
Several cytoplasmic aaRSs have been discovered in different
genetic screens in flies. Aspartyl-tRNA synthetase (AspRS) was
independently identified in screens for Sex-lethal dosage-sensitive
modifiers26 and for mutants defective in larval growth.27 Trypto-
phanyl-tRNA synthetase (TrpRS) was identified in a screen for
genes expressed in the embryonic salivary gland,17 while muta-
tions in several different cytoplasmic aaRSs were found to
increase lysosomal activity.28 In each case, the specificity and pre-
cise function of the aaRS enzyme(s) involved remain to be
characterized.
Work from our group has characterized the importance of
aminoacylation fidelity in vivo by exploring the ‘double-sieving’
function of PheRS in Drosophila.16 The first sieve — amino-acid
recognition — serves to exclude most non-cognate amino acids;
the second sieve — amino-acid editing — is capable of correcting
aminoacylation errors. Both sieves are important and double-
sieving-defective mutations in PheRS result in misacylation by
non-cognate Tyr and protein mistranslation, leading to many
defects, including ER stress, neuronal cell apoptosis, impaired
locomotive performance, reduced lifespan, and decreased organ
size. This work demonstrates how malfunctioning of aaRSs at
the molecular level can cause a range of phenotypes at the cellular
and organismal levels.
Mitochondrial aminoacyl-tRNA synthetases
Mitochondrial aaRSs are required for protein translation in
this organelle and are thought to have a bacterial origin. In
eukaryotic cells, they are encoded by nuclear genes and, after
being expressed, they are imported into mitochondria with the
guidance of a mitochondrial targeting sequence (MTS29; Fig. 2)
There are 15 genes coding for 15 mitochondrial aaRSs in D. mel-
anogaster (Table 1). In contrast to the situation in the cytoplasm,
the mitochondrial PheRS consists of only one polypeptide
encoded by a single gene while 2 separate genes code for distinct
mitochondrial GluRS and ProRS enzymes. Furthermore, only
ProRS-m is annotated to encode more than one polypeptide (Fly-
Base), though the function of the shorter protein isoform is
unknown. We were unable to identify a GlnRS-m gene in our
analysis, though this is consistent with a lack of GlnRS activity in
all chloroplasts and mitochondria examined.30,31 In these organ-
elles, Gln-tRNA is generated by mischarging a tRNAGln with
Glu and converting Glu to Gln via a heterotrimeric Glu-
tRNAGln amidotransferase (Gat).31,32 In D. melanogaster, the 3
subunits of this complex are encoded by the GatA,33 CG5463
and CG33649 genes – we propose to name the latter two GatB
and GatC, respectively (Table S2).
Drosophila mitochondrial aaRSs have received a similar degree
of attention in the published literature as their cytoplasmic coun-
terparts. The sequence and structure of the fly PheRS-m was
described in a comparative study with the human enzyme.34
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ArgRS-m was identified in a genetic screen for nuclear-encoded
genes with mitochondrial function.35 Its mitochondrial localiza-
tion was confirmed in this study by using a GFP fusion protein.
MetRS-m was identified in a screen for genes required for neuro-
nal survival and function.36 Mutant flies were characterized and
found to exhibit defects in mitochondrial function and cell pro-
liferation. The function of SerRS-m was analyzed through an
RNAi approach.37 This was shown to specifically reduce seryla-
tion of mitochondrial tRNAs, resulting in defective mitochon-
drial translation and function. AlaRS-m was studied to address
how it distinguishes mitochondrial tRNAAla from the cyto-
plasmic tRNAAla.38,39 Another series of experiments explored the
compatibility between mitochondria-encoded tRNAs and their
nucleus-encoded mitochondrial aaRSs.40-42 While individual
mutations in a mitochondrial tRNATyr gene and a mitochondrial
TyrRS-m showed few phenotypic effects on their own, these
mutations caused severe phenotypes coupled with reduced mito-
chondrial function when combined in the same fly.
Dual-localized aminoacyl-tRNA synthetases
Dual-localized aaRSs are encoded by single genes and perform
aminoacylation of tRNAs in the cytoplasmic and the mitochon-
drial compartments. Our database searches uncovered 4 candi-
date dual-localized aaRSs in D. melanogaster - GlyRS, LysRS,
HisRS, and ThrRS (Table 1). Significantly, and in contrast to
the genes in the other 2 groups, each of these aaRS genes encodes
at least 2 polypeptides. As the mitochondrial version needs an
MTS, it is possible that the shorter polypeptide corresponds to
the cytoplasmic version and the longer one to the mitochondrial
isoform. Indeed, this has been experimentally confirmed for
GlyRS (Fig. 2A)43 and was suggested for LysRS.44 We analyzed
the 2 other aaRSs using Mitoprot, a prediction tool for mito-
chondrial targeting sequences.29 Indeed, HisRS and ThrRS each
encode at least one longer polypeptide with high probability of
mitochondrial localization (Fig. 2B), strongly suggesting that
these enzymes do indeed function as dual-localized aaRSs in
Drosophila.
Despite the high conservation of these enzymes and their
function through evolution, we noticed that the sets of fly and
human dual-localized aaRS genes are not identical. Humans con-
tain only 2 dual-localized aaRS genes, GlyRS and LysRS, while
flies additionally have HisRS and ThrRS. This difference needs to
be considered when modeling human diseases related to these 2
genes in flies.
To obtain a better understanding of how these 4 enzymes
evolved, we performed phylogenetic analyses with sequences
from various eukaryotic species (including flies and human), bac-
teria and archaea (Fig. 3). All eukaryotic species analyzed contain
Figure 2. Dual-localized aaRSs in D. melanogaster. (A) GlyRS is shown as an example of dual-localized aaRS. It encodes 2 polypeptides, PA and PB. PB
contains an extra N-terminal mitochondrial targeting sequence (MTS; in red) that can be used for its import into mitochondria. (B) The four dual-localized
aaRSs with their predicted MTS and probabilities of mitochondrial localization. The analysis was performed by Mitoprot.29 E.C., experimentally
conﬁrmed.
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Figure 3. Phylogenetic analysis of 4 dual-localized aaRSs. Protein sequences of common eukaryotes, archaea, and bacteria were obtained from different
databases (UniProt, Ensembl, HGNC, FlyBase, Xenbase, WormBase), and also by searching with BLAST. The sequences were aligned using Pagan,54 fol-
lowed by TrimAl analysis,55 discarding the poorly aligned columns with the threshold of 60%. The treated multiple sequence alignments were used to
generate the 4 gene trees using PhyML56; for topology searches we chose the best out of the NNI and PhyML-Subtree-Pruning-Regrafting (SPR) meth-
ods.57,58 All parameters were optimized, i.e., tree topology, branch length and the substitution rate. The number of bootstrap replicates was set to 5.
Eukaryotes are shown in yellow, archaea in blue, and bacteria in red. The scale bar stands for the number of substitutions per site.
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a single GlyRS gene, which is more closely related to the one from
archaea than to the bacterial one, suggesting that it originated
from the cytoplasmic aminoacyl-tRNA synthetases. LysRS is also
encoded by a single gene. However, the eukaryotic LysRS is
closer to the bacterial ones, suggesting that it originated from a
mitochondrial gene. Interestingly, lower eukaryotic species con-
tain a single HisRS gene, just like bacteria and archaea, while ver-
tebrates (higher eukaryotes) have 2 separate genes, demonstrating
that splitting up their function into 2 separate genes and enzymes
was beneficial to vertebrates. For ThrRS the available data suggest
that lower eukaryotes may contain only one gene type that was
derived from the bacterial/mitochondrial one. The phylogenetic
tree then further suggests that there was a subsequent split into 2
types, but that this split was only maintained in some of the ana-
lyzed lineages, in the higher vertebrates (mammals). Clearly,
more data points are needed to ascertain the apparently rather
complex evolution of the ThrRS sequences.
GlyRS is the only dual-localized aaRS that has been studied
experimentally in Drosophila. It was initially identified in a
mosaic forward genetic screen for genes having cell-autonomous
functions in dendritic and axonal development.43 While the cyto-
plasmic function of GlyRS was found to be required for terminal
arborization of both dendrites and axons during development,
the mitochondrial function is preferentially required for the
maintenance of dendritic terminals in adults.
Drosophila as a model for aaRS-associated human diseases
Mutations in multiple aaRSs have been implicated in several
different human diseases, though the mechanistic details are
obscure in most cases.7 Researchers have begun to use the power
and efficiency of Drosophila genetics to model some of these dis-
eases, and in so doing more readily investigate their molecular
and cellular basis.
Charcot-Marie-Tooth (CMT) neuropathies affect the periph-
eral nervous system and are associated with axonal degeneration,
distal muscle wasting and progressive motor impairment.45
Mutations in the human YARS gene, encoding the cytoplasmic
TyrRS, cause dominant-intermediate CMT type C (DI-
CMTC).46 Transgenic expression of either human or Drosophila
TyrRS bearing disease-associated mutations in flies recapitulated
several hallmarks of the human pathology, including progressive
decreases in motor performance and axonal degeneration.15,47 By
virtue of studying these effects in flies, the authors were able to
conclude that the disease phenotypes are not caused by reduced
aminoacylation activity, but are more likely due to a gain-of-
function alteration of the mutant TyrRS or interference with a
non-canonical function.47 This Drosophila disease model was
also demonstrated to be a useful and rapid platform for screening
the pathogenicity of novel candidate YARS mutations.15
Mutations in a second human aaRS gene, GARS (encoding
the dual-localized GlyRS enzyme), cause a different CMT sub-
type, CMT type 2D (CMT2D).48 An initial study in flies
found that loss-of-function mutations in the native Drosophila
GlyRS gene resulted in neuronal phenotypes consistent with
CMT2D symptoms in humans, although transgenic expression
of disease-associated GARS mutations in neuronal clones had no
morphological effect.43 A recent study generated a more realistic
Drosophila model for CMT2D through ubiquitous or pan-neu-
ronal expression of fly GlyRS transgenes with alterations equiva-
lent to those of pathogenic GARS mutations. These transgenic
flies showed both morphological and behavioral phenotypes
that recapitulated the human disease.49 Significantly, these phe-
notypes were observed for disease-associated GlyRS mutants that
maintained aminoacylation activity, suggesting that CMT2D is
the result of a toxic, neomorphic activity, similar to the conclu-
sion from the DI-CMTC model. A subsequent study confirmed
these observations, and further suggested that the gain-of-func-
tion effects have a non-cell autonomous contribution.50 Other
recent work has generated a complementary Drosophila model
of CMT2D in flies through expression of human GARS trans-
genes harboring disease-associated mutations.51 The disease-rele-
vant phenotypes were again found not to correlate with reduced
aminoacylation activity of the enzyme. Nevertheless, a marked
decrease in global protein synthesis in motor and sensory neu-
rons was observed in the transgenic flies, suggesting that the
mutant enzymes inhibit translation through a cell autonomous
mechanism independent of their aminoacylation function.
Interestingly, expression of DI-CMTC-associated YARS mutants
also resulted in translation inhibition in this assay.51 This find-
ing, together with the facts that the phenotypes of the fly mod-
els of both CMT subtypes are similar and share common
genetic modifiers,49 suggests that a common mechanism may
underlie both YARS- and GARS-associated CMT neuropathies.
Fly MetRS-m was identified in a screen for genes required for
neuronal survival and function.36 Mutant flies exhibited defects
in mitochondrial function, cell proliferation and age-dependent
retinal and muscle degeneration. Remarkably, these findings led
to the discovery that mutations in the orthologous human gene,
MARS2, are responsible for the neurodegenerative disease Auto-
somal Recessive Spastic Ataxia with Leukoencephalopathy
(ARSAL). Similar to flies, cells from ARSAL patients showed
aberrant mitochondrial function and proliferation. This study
also reported that treatment with antioxidants could suppress the
fly mutant phenotypes, indicating a possible treatment for the
human disease.
A different study utilized RNAi to target SerRS-m to produce
a fly model of human mitochondrial aminoacylation pathologies
in general and mitochondrial serylation defects in particular.37
For example, the fly phenotypes reproduce traits seen in MELAS
(mitochondrial encephalomyopathy, lactic acidosis and stroke-
like episodes) or MERRF (myoclonic epilepsy with ragged red
fibers), as well as HUPRA syndrome (hyperuricemia, pulmonary
hypertension, renal failure in infancy and alkalosis), the latter of
which is caused by a mutation in the orthologous SARS2 gene.
Furthermore, it was found that antioxidant treatment amelio-
rated the phenotypes resulting from SerRS-m silencing,37 similar
to theMetRS-m study.36
Finally, Drosophila TyrRS-m has been studied as a general
model for human mitochondrial diseases stemming from an
incompatibility between the nuclear-encoded aaRSs and mito-
chondrially-encoded tRNAs.42 In this model, a mutation in
TyrRS-m resulted in defective mitochondrial dysfunction and
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locomotor defects, though the severity varied across different
genetic backgrounds and traits. These context-dependent pheno-
types mirror the symptoms of the MLASA syndrome (mitochon-
drial myopathy, lactic acidosis and sideroblastic anemia) that
results from mutations in the orthologous human gene YARS2.
In summary, several different aaRS-associated human diseases
have so far been effectively modeled in Drosophila using a variety
of genetic techniques. These approaches have generated a number
of clinically important conclusions, including insights into etiol-
ogy of CMT15,47,49-51 and the discovery of the underlying cause
of ARSAL.36 Moreover, some of these studies have isolated
modifiers of the disease model,36,37,49 demonstrating a further
advantage of using the Drosophila system.
Conclusion
Most studies of aaRS biology in Drosophila to date have either
investigated their canonical functions or have used mutant geno-
types to produce models of human diseases linked to aaRS dys-
function. In addition, several aaRSs have been identified in
diverse genetic screens, though their precise role in these condi-
tions remains unclear. Notably, the non-canonical roles of aaRSs
that have been described in other systems have so far received
sparse attention in Drosophila, while many aaRS-associated
human diseases have yet to be modeled in flies. Based on these
considerations we predict an increase in such studies in the near
future. The systematic identification and logical naming of the
D. melanogaster aaRSs presented here, together with our literature
survey, will aid all these lines of investigation, and thereby
facilitate further discoveries into both the normal and aberrant
mechanisms of action of these essential and fascinating enzymes.
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